The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended four new medicines and three biosimilars for approval at its November meeting.
The CHMP recommended granting a marketing authorization for Afstyla (lonoctocog alfa) for the prevention and treatment of bleeding in patients with hemophilia A, from CSL Behring, a subsidiary of Australia’ CSL Limited (ASX: CSL). The drug was approved by theUS Food and Drug Administration in May this year.
Vemlidy (tenofovir alafenamide) received a positive opinion from the CHMP for the treatment of chronic hepatitis B from US biotech firm Gilead Sciences (Nasdaq: GILD). The recommendation comes just a day after the US FDA approved the drug for marketing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze